Quantitation of the Ataxia-telangiectasia-mutated and Rad3-related Inhibitor Elimusertib (BAY-1895344) in Human Plasma Using LC-MS/MS

Overview

Journal Biomed Chromatogr

Publisher Wiley

Specialties Biology
Chemistry

Date 2022 Jul 25

PMID 35876841

Authors

Brian F Kiesel

Robert A Parise

Anuradha Krishnamurthy

Steven Gore

Jan H Beumer

Affiliations

Soon will be listed here.

Abstract

Ataxia-telangiectasia-mutated and Rad3-related (ATR) is master regulator of the DNA-damage response that, through multiple mechanisms, can promote cancer cell survival in response to replication stress from sources, including chemotherapy and radiation. Elimusertib (BAY-1895344) is an orally available small-molecule ATR inhibitor currently in preclinical and clinical development for cancer treatment. To support these studies and define elimusertib pharmacokinetics, we developed a HPLC-MS method for its quantitation. A 50-μL volume of plasma was subjected to acetonitrile protein precipitation and then chromatographic separation using a Phenomenex Polar-RP column (2 × 50 mm, 4 μm) and a gradient mobile phase consisting of 0.1% formic acid in acetonitrile and water during a 7-min run time. Mass spectrometric detection was achieved using a SCIEX 4000 triple-stage mass spectrometer with electrospray positive-mode ionization. With a stable isotopic internal standard, the assay was linear from 30 to 5000 ng/mL and proved to be both accurate (93.5-108.2%) and precise (<6.3% coefficient of variation) fulfilling criteria from the Food and Drug Administration guidance on bioanalytical method validation. This LC-MS/MS assay will support several ongoing clinical studies by defining elimusertib pharmacokinetics.

References

Little J, Wempe M, Buchanan C . Liquid chromatography-mass spectrometry/mass spectrometry method development for drug metabolism studies: Examining lipid matrix ionization effects in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2006; 833(2):219-30. DOI: 10.1016/j.jchromb.2006.02.011. View

Canman C . Replication checkpoint: preventing mitotic catastrophe. Curr Biol. 2001; 11(4):R121-4. DOI: 10.1016/s0960-9822(01)00057-4. View

Toledo L, Murga M, Zur R, Soria R, Rodriguez A, Martinez S . A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol. 2011; 18(6):721-7. PMC: 4869831. DOI: 10.1038/nsmb.2076. View

Lucking U, Wortmann L, Wengner A, Lefranc J, Lienau P, Briem H . Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models. J Med Chem. 2020; 63(13):7293-7325. DOI: 10.1021/acs.jmedchem.0c00369. View

Dunne V, Ghita M, Small D, Coffey C, Weldon S, Taggart C . Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small cell lung cancer (NSCLC) radiotherapy. Radiother Oncol. 2017; 124(3):475-481. DOI: 10.1016/j.radonc.2017.06.025. View

Singh S . Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab. 2006; 7(2):165-82. DOI: 10.2174/138920006775541552. View

Sun L, Yang R, Li C, Chen M, Shao B, Hsu J . Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. Am J Cancer Res. 2018; 8(7):1307-1316. PMC: 6079156. View

Dillon M, Bergerhoff K, Pedersen M, Whittock H, Crespo-Rodriguez E, Patin E . ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment. Clin Cancer Res. 2019; 25(11):3392-3403. PMC: 6551222. DOI: 10.1158/1078-0432.CCR-18-1821. View

Reaper P, Griffiths M, Long J, Charrier J, MacCormick S, Charlton P . Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol. 2011; 7(7):428-30. DOI: 10.1038/nchembio.573. View

10.

Dillon M, Boylan Z, Smith D, Guevara J, Mohammed K, Peckitt C . PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with.... Clin Transl Radiat Oncol. 2018; 12:16-20. PMC: 6068075. DOI: 10.1016/j.ctro.2018.06.001. View

11.

Kwok M, Davies N, Agathanggelou A, Smith E, Petermann E, Yates E . Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway. Lancet. 2015; 385 Suppl 1:S58. DOI: 10.1016/S0140-6736(15)60373-7. View

12.

Wengner A, Siemeister G, Lucking U, Lefranc J, Wortmann L, Lienau P . The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models. Mol Cancer Ther. 2019; 19(1):26-38. DOI: 10.1158/1535-7163.MCT-19-0019. View

13.

Yap T, OCarrigan B, Penney M, Lim J, Brown J, De Miguel Luken M . Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. J Clin Oncol. 2020; 38(27):3195-3204. PMC: 7499606. DOI: 10.1200/JCO.19.02404. View

14.

McLaughlin M, Patin E, Pedersen M, Wilkins A, Dillon M, Melcher A . Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020; 20(4):203-217. DOI: 10.1038/s41568-020-0246-1. View

15.

Vendetti F, Karukonda P, Clump D, Teo T, Lalonde R, Nugent K . ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J Clin Invest. 2018; 128(9):3926-3940. PMC: 6118586. DOI: 10.1172/JCI96519. View

16.

Mei L, Zhang J, He K, Zhang J . Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. J Hematol Oncol. 2019; 12(1):43. PMC: 6482552. DOI: 10.1186/s13045-019-0733-6. View

17.

Awasthi P, Foiani M, Kumar A . ATM and ATR signaling at a glance. J Cell Sci. 2015; 128(23):4255-62. DOI: 10.1242/jcs.169730. View

18.

Cheung-Ong K, Giaever G, Nislow C . DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem Biol. 2013; 20(5):648-59. DOI: 10.1016/j.chembiol.2013.04.007. View

19.

Yap T, Tan D, Terbuch A, Caldwell R, Guo C, Goh B . First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. Cancer Discov. 2020; 11(1):80-91. PMC: 9554790. DOI: 10.1158/2159-8290.CD-20-0868. View

20.

Bouwman P, Jonkers J . The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat Rev Cancer. 2012; 12(9):587-98. DOI: 10.1038/nrc3342. View